Welcome to our dedicated page for Arteris SEC filings (Ticker: AIP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Arteris, Inc. filings document a semiconductor technology business built around System IP for SoC and chiplet design. Its 8-K reports cover quarterly and annual operating results, financial-condition updates, guidance exhibits, customer shipment milestones, royalty trends and product portfolio disclosures for network-on-chip interconnect IP, SoC integration automation software and hardware security assurance.
The company’s proxy materials cover board elections, executive compensation, equity incentive arrangements and stockholder voting matters. They also describe governance and business context for Arteris’ markets, including automotive, artificial intelligence and machine learning, 5G communications, data centers, edge computing, enterprise and consumer electronics.
Arteris, Inc. (AIP) reported Q3 2025 results with total revenue of $17.4 million, up from $14.7 million a year ago as licensing, support and maintenance reached $15.9 million and variable royalties were $1.5 million. Gross profit was $15.6 million on a 90% gross margin profile. Operating expenses rose to $24.4 million, leading to a net loss of $9.0 million versus $7.7 million last year, or $0.21 per share.
The company ended September 30, 2025 with $17.4 million in cash and cash equivalents and $43.2 million in total investments. Deferred revenue was $85.9 million, and remaining performance obligations were $104.7 million. Annual Contract Value was $69.4 million, with ACV plus royalties at $74.9 million as of September 30, 2025. Net cash provided by operating activities for the nine months was $3.6 million.
Arteris reported 23 Confirmed Design Starts in the quarter. As of October 28, 2025, there were 43,683,773 common shares outstanding. In litigation, on September 4, 2024, a Texas federal court dismissed all claims against the company without prejudice in the NST matter.
Arteris, Inc. (AIP) reported Q3 2025 results with total revenue of $17.4 million, up from $14.7 million a year ago as licensing, support and maintenance reached $15.9 million and variable royalties were $1.5 million. Gross profit was $15.6 million on a 90% gross margin profile. Operating expenses rose to $24.4 million, leading to a net loss of $9.0 million versus $7.7 million last year, or $0.21 per share.
The company ended September 30, 2025 with $17.4 million in cash and cash equivalents and $43.2 million in total investments. Deferred revenue was $85.9 million, and remaining performance obligations were $104.7 million. Annual Contract Value was $69.4 million, with ACV plus royalties at $74.9 million as of September 30, 2025. Net cash provided by operating activities for the nine months was $3.6 million.
Arteris reported 23 Confirmed Design Starts in the quarter. As of October 28, 2025, there were 43,683,773 common shares outstanding. In litigation, on September 4, 2024, a Texas federal court dismissed all claims against the company without prejudice in the NST matter.
Arteris, Inc. furnished a Form 8‑K stating it issued a press release with financial results for the quarter ended September 30, 2025. The press release is provided as Exhibit 99.1 and incorporated by reference.
The company noted that the information in Items 2.02 and 9.01, including Exhibit 99.1, is being furnished and not deemed “filed” under the Exchange Act. Arteris’ common stock trades on Nasdaq under the symbol AIP.
Arteris, Inc. furnished a Form 8‑K stating it issued a press release with financial results for the quarter ended September 30, 2025. The press release is provided as Exhibit 99.1 and incorporated by reference.
The company noted that the information in Items 2.02 and 9.01, including Exhibit 99.1, is being furnished and not deemed “filed” under the Exchange Act. Arteris’ common stock trades on Nasdaq under the symbol AIP.
Arteris, Inc. reporting person Janac K. Charles disclosed insider sales executed under a 10b5-1 trading plan adopted on 03/05/2025. The filing shows a weighted-average sale of $13.0742 for 50,000 shares sold on 10/08/2025. After the reported transactions, the reporting person is listed as having 9,689,071 shares beneficially owned indirectly through Bayview Legacy, LLC, and additional holdings are noted through the Charles and Lydia Janac Trust. The report was signed by an attorney-in-fact on 10/10/2025. The sale is identified as made pursuant to a pre-established trading plan and the filing discloses the range of execution prices between $13.00 and $13.20.
Arteris, Inc. (AIP) reporting person Bayview Legacy, LLC (managed by K. Charles Janac) sold 50,000 shares of common stock on 10/08/2025 under a pre-existing 10b5-1 trading plan. The weighted average sale price was $13.0742 (individual trades ranged from $13.00 to $13.20). After the sale, Bayview Legacy, LLC is reported to beneficially own 9,689,071 shares indirectly through the manager relationship. The filing notes that Janac separately filed an individual Form 4 to report the same transaction and confirms he is deemed to have voting and dispositive power over the shares held by Bayview Legacy, LLC.
Insider sale under 10b5-1 plan. The filing shows that Nicholas B. Hawkins, Vice President and Chief Financial Officer of Arteris, Inc. (AIP), sold 6,421 shares of common stock on 10/07/2025 at a weighted average price of $13.2073 per share. The report states the sales were executed under a 10b5-1 trading plan adopted on 06/04/2025. After the transactions, Hawkins beneficially owned 93,590 shares. The filer notes the sale prices ranged from $12.85 to $14.11 and offers to disclose per‑price quantities on request.
Arteris, Inc. director, president and CEO Janac K. Charles reported sales under a pre-established 10b5-1 plan. On 10/06/2025 the reporting person sold 5,755 shares at a listed price of $14 and sold an additional 100,000 shares at a weighted average price of $13.1045 (individual trades ranged from $12.50 to $13.85). After these transactions, direct beneficial ownership is reported as 161,759 shares and indirect ownership through entities is 9,739,071 shares. The filing notes the sales were executed pursuant to a trading plan adopted on 03/05/2025.
Arteris, Inc. insider filing reports that Bayview Legacy, LLC, an entity managed by K. Charles Janac, sold 100,000 shares of Arteris common stock on 10/06/2025 under a 10b5-1 trading plan. The sales were executed in multiple transactions at weighted-average price $13.1045, with trade prices ranging from $12.50 to $13.85. After the disposition, Bayview Legacy, LLC is reported to beneficially own 9,739,071 shares, and Janac is deemed to have voting and dispositive power as the manager. Janac also filed a separate Form 4 reporting the same sale in his individual capacity.
Arteris, Inc. director Antonio J. Viana reported insider sales on 10/06/2025. The filing shows a sale of 11,841 shares of common stock at a price of $14 and an additional disposal of 20,840 common shares. After these transactions the reporting person is listed as beneficially owning 184,620 shares indirectly through the Viana Family Trust. The sales were made under a pre-existing Rule 10b5-1 trading plan that the reporting person adopted on 06/10/2025, and the Form 4 was signed by an attorney-in-fact on 10/06/2025. The filing presents routine, planned insider disposals rather than unscheduled or ad-hoc trades.
Arteris, Inc. (AIP) submitted a Rule 144 notice proposing the sale of 50,000 common shares through Morgan Stanley Smith Barney LLC for an aggregate market value of $647,500. The notice lists the company's total outstanding shares as 42,649,917 and an approximate sale date of 10/08/2025. The shares were originally acquired from the issuer in a private transaction on 11/05/2013 and were paid for in cash. The filing also discloses multiple recent sales by related parties and 10b5-1 plans in the past three months, including transactions dated 08/05/2025, 09/02/2025, and 10/06/2025, with amounts ranging up to $1,310,450.00 in gross proceeds for a single sale.
Arteris, Inc. filing a Form 144 notifies a proposed sale of 6,421 common shares (acquired as restricted stock units) with an aggregate market value of $87,197.18, through Morgan Stanley Smith Barney LLC on or about 10/07/2025. The RSUs were recorded as acquired on 10/01/2025 and the filing lists previous sales by the same person totaling 30,538 shares during the prior three months, generating gross proceeds of $336,546.61. The filer affirms no undisclosed material adverse information and references Rule 10b5-1 sales plans used for several prior transactions.